Caribou Retained Earnings from 2010 to 2024

CRBU Stock

USD 2.02 0.04 2.02%

Caribou Biosciences Retained Earnings yearly trend continues to be comparatively stable with very little volatility. Retained Earnings are likely to outpace its year average in 2024. Retained Earnings is the cumulative amount of net income that Caribou Biosciences retains for reinvestment in its operations, rather than distributing it to shareholders as dividends. View All Fundamentals

Retained Earnings

First Reported

2010-12-31

Previous Quarter

-299.3 M

Current Value

-284.3 M

Quarterly Volatility

109.8 M

Credit Downgrade

Yuan Drop

Covid

Check Caribou Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Caribou Biosciences' main balance sheet or income statement drivers, such as Tax Provision of 202.7 K, Net Interest Income of 119.7 K or Interest Income of 126.5 K, as well as many indicators such as Price To Sales Ratio of 11.65, Dividend Yield of 0.0 or PTB Ratio of 1.09. Caribou financial statements analysis is a perfect complement when working with Caribou Biosciences Valuation or Volatility modules.

Check out the analysis of Caribou Biosciences Correlation against competitors.

For more information on how to buy Caribou Stock please use our How to Invest in Caribou Biosciences guide.

Latest Caribou Biosciences' Retained Earnings Growth Pattern

Below is the plot of the Retained Earnings of Caribou Biosciences over the last few years. It is the cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends. Caribou Biosciences' Retained Earnings historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Caribou Biosciences' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported (299.29 M)

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Retained Earnings

Timeline

Caribou Retained Earnings Regression Statistics

	Arithmetic Mean	(58,341,050)
	Coefficient Of Variation	(188.26)
	Mean Deviation	86,033,407
	Median	3,437,000
	Standard Deviation	109,832,079
	Sample Variance	12063.1T
	Range	302.7M
	R-Value	(0.78)
	Mean Square Error	5151.9T
	R-Squared	0.60
	Significance	0.0007
	Slope	(19,077,658)
	Total Sum of Squares	168883.2T

Caribou Retained Earnings History

	2024	-284.3 M
	2023	-299.3 M
	2022	-197.2 M
	2021	-97.8 M
	2020	-30.9 M

Other Fundumenentals of Caribou Biosciences

Retained Earnings Total Equity

Caribou Biosciences Retained Earnings component correlations

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Short Term Investments	Total Liab	Net Invested Capital	Short Long Term Debt	Total Current Assets	Capital Stock	Net Working Capital	Short Term Debt	Common Stock	Property Plant Equipment	Long Term Debt	Capital Surpluse	Deferred Long Term Liab
Total Assets		1.0	1.0	0.86	-0.46	-0.86	0.18	0.53	0.89	0.66	1.0	0.83	0.99	0.99	0.99	0.63	0.99	0.78	-0.49	0.66	-0.49
Total Stockholder Equity	1.0		1.0	0.86	-0.48	-0.84	0.2	0.54	0.88	0.64	1.0	0.83	1.0	0.98	0.99	0.65	0.98	0.77	-0.48	0.65	-0.48
Net Tangible Assets	1.0	1.0		0.87	-0.52	-0.81	0.21	0.57	0.84	0.61	1.0	0.82	0.99	0.97	0.99	0.68	0.97	0.76	-0.41	0.61	-0.41
Current Deferred Revenue	0.86	0.86	0.87		-0.52	-0.64	-0.09	0.63	0.69	0.67	0.86	0.66	0.84	0.79	0.84	0.67	0.79	0.58	-0.24	0.27	-0.24
Net Debt	-0.46	-0.48	-0.52	-0.52		0.0	-0.69	-0.9	-0.1	0.24	-0.48	-0.22	-0.55	-0.32	-0.56	-0.97	-0.32	0.12	-0.17	0.2	-0.17
Retained Earnings	-0.86	-0.84	-0.81	-0.64	0.0		0.1	-0.14	-0.99	-0.84	-0.85	-0.82	-0.81	-0.91	-0.8	-0.21	-0.91	-0.84	0.8	-0.9	0.8
Accounts Payable	0.18	0.2	0.21	-0.09	-0.69	0.1		0.56	-0.05	-0.55	0.2	0.13	0.29	0.12	0.3	0.62	0.12	-0.23	0.06	0.03	0.06
Net Receivables	0.53	0.54	0.57	0.63	-0.9	-0.14	0.56		0.19	0.01	0.54	0.49	0.59	0.41	0.6	0.96	0.41	-0.04	0.12	-0.14	0.12
Short Term Investments	0.89	0.88	0.84	0.69	-0.1	-0.99	-0.05	0.19		0.8	0.88	0.78	0.86	0.92	0.85	0.29	0.92	0.81	-0.81	0.87	-0.81
Total Liab	0.66	0.64	0.61	0.67	0.24	-0.84	-0.55	0.01	0.8		0.64	0.72	0.57	0.71	0.55	-0.01	0.71	0.79	-0.56	0.62	-0.56
Net Invested Capital	1.0	1.0	1.0	0.86	-0.48	-0.85	0.2	0.54	0.88	0.64		0.83	1.0	0.98	0.99	0.65	0.98	0.77	-0.48	0.65	-0.48
Short Long Term Debt	0.83	0.83	0.82	0.66	-0.22	-0.82	0.13	0.49	0.78	0.72	0.83		0.8	0.87	0.79	0.44	0.87	0.72	-0.45	0.66	-0.45
Total Current Assets	0.99	1.0	0.99	0.84	-0.55	-0.81	0.29	0.59	0.86	0.57	1.0	0.8		0.96	1.0	0.7	0.96	0.71	-0.47	0.63	-0.47
Capital Stock	0.99	0.98	0.97	0.79	-0.32	-0.91	0.12	0.41	0.92	0.71	0.98	0.87	0.96		0.96	0.51	1.0	0.86	-0.54	0.76	-0.54
Net Working Capital	0.99	0.99	0.99	0.84	-0.56	-0.8	0.3	0.6	0.85	0.55	0.99	0.79	1.0	0.96		0.71	0.96	0.7	-0.47	0.62	-0.47
Short Term Debt	0.63	0.65	0.68	0.67	-0.97	-0.21	0.62	0.96	0.29	-0.01	0.65	0.44	0.7	0.51	0.71		0.51	0.06	0.04	-0.04	0.04
Common Stock	0.99	0.98	0.97	0.79	-0.32	-0.91	0.12	0.41	0.92	0.71	0.98	0.87	0.96	1.0	0.96	0.51		0.86	-0.54	0.76	-0.54
Property Plant Equipment	0.78	0.77	0.76	0.58	0.12	-0.84	-0.23	-0.04	0.81	0.79	0.77	0.72	0.71	0.86	0.7	0.06	0.86		-0.44	0.79	-0.44
Long Term Debt	-0.49	-0.48	-0.41	-0.24	-0.17	0.8	0.06	0.12	-0.81	-0.56	-0.48	-0.45	-0.47	-0.54	-0.47	0.04	-0.54	-0.44		-0.83	1.0
Capital Surpluse	0.66	0.65	0.61	0.27	0.2	-0.9	0.03	-0.14	0.87	0.62	0.65	0.66	0.63	0.76	0.62	-0.04	0.76	0.79	-0.83		-0.83
Deferred Long Term Liab	-0.49	-0.48	-0.41	-0.24	-0.17	0.8	0.06	0.12	-0.81	-0.56	-0.48	-0.45	-0.47	-0.54	-0.47	0.04	-0.54	-0.44	1.0	-0.83

Click cells to compare fundamentals

About Caribou Biosciences Financial Statements

Caribou Biosciences shareholders use historical fundamental indicators, such as Retained Earnings, to determine how well the company is positioned to perform in the future. Although Caribou Biosciences investors may analyze each financial statement separately, they are all interrelated. The changes in Caribou Biosciences' assets and liabilities, for example, are also reflected in the revenues and expenses on on Caribou Biosciences' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.

	Last Reported	Projected for Next Year
Retained Earnings	-299.3 M	-284.3 M
Retained Earnings Total Equity	-177.5 M	-186.4 M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Caribou Stock Analysis

When running Caribou Biosciences' price analysis, check to measure Caribou Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Caribou Biosciences is operating at the current time. Most of Caribou Biosciences' value examination focuses on studying past and present price action to predict the probability of Caribou Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Caribou Biosciences' price. Additionally, you may evaluate how the addition of Caribou Biosciences to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC